OxTalks will soon move to the new Halo platform and will become 'Oxford Events.' There will be a need for an OxTalks freeze. This was previously planned for Friday 14th November – a new date will be shared as soon as it is available (full details will be available on the Staff Gateway).
In the meantime, the OxTalks site will remain active and events will continue to be published.
If staff have any questions about the Oxford Events launch, please contact halo@digital.ox.ac.uk
Nitric oxide (NO) is a ubiquitous signaling molecule with complex, context-dependent roles in human physiology. Dysregulated NO production contributes to the progression of various diseases, notably affecting women’s health in areas such as pregnancy, autoimmune disorders, cardiovascular conditions, endometriosis, chronic pain, and postmenopausal complications. Despite its therapeutic potential, drug development targeting the NO pathway remains challenging due to its pleiotropic effects and systemic nature.
Our research focuses on harnessing the therapeutic potential of NO through precise and controlled modulation. We are developing stimuli-responsive NO donors and novel peptides that selectively inhibit inducible nitric oxide synthase (iNOS) in a targeted manner. This approach aims to deliver tissue-specific therapeutic effects, minimizing systemic side effects and addressing the limitations of current NO-modulating therapies.
